Literature DB >> 22670895

Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster.

Fumitake Ono1, Shinichiro Yasumoto, Minao Furumura, Takahiro Hamada, Norito Ishii, Takashi Gyotoku, Mitsunari Higuchi, Kenichiro Inokuchi, Kazuo Jyo, Hideaki Koga, Ayako Komai, Koji Maruta, Tami Mashiko, Tsukasa Mihara, Hiroko Miyahara, Minoru Miyasato, Koichiro Muto, Koichi Nagase, Masakazu Nagata, Hideki Sakihama, Tomoko Tanahashi, Atsuto Ueda, Kyoko Yamakawa, Chika Ohata, Teruki Dainichi, Daisuke Tsuruta, Takashi Hashimoto.   

Abstract

Famciclovir is a guanine analog antiviral drug used commonly for herpes zoster. Efficacy of famciclovir treatment has been reported to be comparable to valacyclovir treatment. Both of these medications reduce the time to complete cessation of zoster-associated pain including post-herpetic neuralgia, as compared to acyclovir. We conducted a multicenter, randomized, open clinical trial in order to evaluate the extent of pain relief afforded by these two antiviral drugs during the acute disease phase of herpes zoster. The study group comprised 86 immunocompetent adult patients suffering from herpes zoster, who were treated with either famciclovir or valacyclovir for 7 days. Of these, 55 patients enrolled in this study within 72 h of the onset of the rash and 31 patients after 72 h of the onset. There was a significant reduction in acute herpes zoster pain with famciclovir on day 7 and at 2-3 weeks in both of these patient groups, while with valacyclovir, there was not significant reduction in pain on day 7. Of patients aged 50 years or older, there was a significantly earlier reduction in pain with famciclovir than with valacyclovir. In addition, a significant reduction in the number of patients with pain was observed as early as days 3-4 with famciclovir treatment as compared with valacyclovir treatment. We conclude that famciclovir was superior to valacyclovir in the relief of acute pain of herpes zoster. Accordingly, famciclovir is recommended for herpes zoster patients with moderate symptoms and a visual analog scale score of under 50 mm.
© 2012 Japanese Dermatological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22670895     DOI: 10.1111/j.1346-8138.2012.01584.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  6 in total

1.  [Diagnostics and management of herpes zoster ophthalmicus].

Authors:  R N Werner; N-I Steinhorst; A Nast; U Pleyer
Journal:  Ophthalmologe       Date:  2017-10       Impact factor: 1.059

2.  Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.

Authors:  Kevin J Friesen; Dan Chateau; Jamie Falk; Silvia Alessi-Severini; Shawn Bugden
Journal:  BMC Infect Dis       Date:  2017-01-13       Impact factor: 3.090

Review 3.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

4.  Efficacy of valacyclovir and famciclovir in herpes zoster: A comparative study.

Authors:  Ankita Bist; A Savitha; Kashinath M Gumma
Journal:  Indian J Pharmacol       Date:  2020 Nov-Dec       Impact factor: 1.200

5.  The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study.

Authors:  Kevin J Friesen; Silvia Alessi-Severini; Dan Chateau; Jamie Falk; Shawn Bugden
Journal:  Clinicoecon Outcomes Res       Date:  2016-05-20

6.  Safety and Efficacy of Different Systemic Treatment Modalities for Acute Pain of Herpes Zoster: A Pilot Study.

Authors:  Sanjiv Choudhary; Shivani Dhande; Sachin Kharat; A L Singh
Journal:  Indian Dermatol Online J       Date:  2018 Mar-Apr
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.